6533b859fe1ef96bd12b6fb6

RESEARCH PRODUCT

5-Year Outcome of Pulmonary Vein Isolation by Loss of Pace Capture on the Ablation Line Versus Electrical Circumferential Pulmonary Vein Isolation

Stephan WillemsDoreen SchreiberHelge ServatiusBenjamin SchäfferTim SalzbrunnBoris A. HoffmannDaniel StevenJulia MoserJakob LükerJulia VoglerArian SultanManuel AltenburgRuken Ö. Akbulak

subject

Malemedicine.medical_specialtymedicine.medical_treatmentElectric Stimulation TherapyCatheter ablation030204 cardiovascular system & hematologyPulmonary veinlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialRecurrencelawInternal medicineAtrial FibrillationClinical endpointHumansMedicine030212 general & internal medicineAtrial tachycardiaAgedbusiness.industryCardiac Pacing ArtificialAtrial fibrillationMiddle AgedAblationmedicine.diseaseSurgeryCatheterTreatment OutcomePulmonary VeinsCatheter AblationCardiologyFemalemedicine.symptombusinessFollow-Up Studies

description

This study sought to compare long-term arrhythmia-free survival between electrical circumferential pulmonary vein isolation (PVI) and PVI with the endpoint of unexcitability along the ablation line.PVI is the standard ablation strategy of paroxysmal atrial fibrillation, although arrhythmia recurrence in long-term follow-up (FU) is high. The endpoint of unexcitability along the ablation line results in decreased arrhythmia recurrence compared to electrical PVI in 1-year FU.Seventy-four consecutive patients (age 62.5 ± 10.6 years; 70.3% male) with de novo paroxysmal atrial fibrillation who were initially included in our randomized trial and underwent catheter ablation at our institution were analyzed. Patients who were randomized to either a conventional group (PVI, guided by circumferential catheter signals) or a pace-guided group (PG, anatomical ablation line encircling, ablation until loss of pace capture at 10 V, 2-ms pulse width on the ablation line) underwent long-term FU. The primary endpoint was recurrence of any atrial fibrillation or atrial tachycardia after a blanking period of 3 months.Sixty-nine patients completed a mean FU period of 5.14 ± 0.98 years. Arrhythmia-free survival without antiarrhythmic drug therapy was significantly higher in the PG group (71.05% vs. 25.81%, p = 0.002). Furthermore, multiple procedure success (1.29 ± 0.61 procedures in PG vs. 1.97 ± 1.06 procedures in conventional group, p 0.001) was higher in the PG group compared to the conventional group (89.47% vs. 58.06%, p = 0.005).The endpoint of unexcitability along the PVI line improves success rates, resulting in a significant reduction of exposure to invasive procedures in 5-year FU.

https://doi.org/10.1016/j.jacep.2017.04.019